Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
Background Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-assoc...
Saved in:
| Published in | Journal of neuroinflammation Vol. 16; no. 1; pp. 134 - 12 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
02.07.2019
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1742-2094 1742-2094 |
| DOI | 10.1186/s12974-019-1525-1 |
Cover
| Abstract | Background
Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease.
Methods
This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment.
Results
Median age at onset was 34.1 years (range 18.0–67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1–89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20–0.82;
p
= 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (
n
= 11;
p
= 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (
n
= 11;
p
= 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (
n
= 26;
p
= 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide;
n
= 5), or multiple sclerosis disease-modifying drugs (MS-DMD;
n
= 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab.
Conclusion
In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD. |
|---|---|
| AbstractList | Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease. This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged [greater than or equai to] 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment. Median age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab. In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD. Abstract Background Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease. Methods This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment. Results Median age at onset was 34.1 years (range 18.0–67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1–89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20–0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab. Conclusion In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD. Background Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease. Methods This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment. Results Median age at onset was 34.1 years (range 18.0–67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1–89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20–0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine ( n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF ( n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab ( n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab. Conclusion In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD. Background Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease. Methods This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged [greater than or equai to] 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment. Results Median age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab. Conclusion In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD. Keywords: MOG antibodies, Treatment response, Neuromyelitis optica, Multiple sclerosis, Propensity score Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease.BACKGROUNDMyelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease.This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment.METHODSThis is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment.Median age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab.RESULTSMedian age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab.In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD.CONCLUSIONIn adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD. BACKGROUND:Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease.METHODS: This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment.RESULTS: Median age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab.CONCLUSION: In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD. Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease. This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment. Median age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab. In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD. |
| ArticleNumber | 134 |
| Audience | Academic |
| Author | Bourre, Bertrand Marignier, Romain Labauge, Pierre Solà-Valls, Nuria Cohen, Mikael Maillart, Elisabeth Ayrignac, Xavier Armangué, Thais Sepúlveda, María Deschamps, Romain Zephir, Helene Rollot, Fabien Montcuquet, Alexis Audoin, Bertrand Ruiz, Anne Ciron, Jonathan Saiz, Albert Collongues, Nicolas De Seze, Jerome Papeix, Caroline Blanco, Yolanda Vukusic, Sandra Cobo-Calvo, Alvaro Biotti, Damien Durand-Dubief, Francoise Llufriu, Sara Thouvenot, Eric |
| Author_xml | – sequence: 1 givenname: Alvaro surname: Cobo-Calvo fullname: Cobo-Calvo, Alvaro organization: Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Lyon Neuroscience Research Center, U1028 INSERM, UMR5292 CNRS, FLUID Team, Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM) – sequence: 2 givenname: María surname: Sepúlveda fullname: Sepúlveda, María organization: Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona – sequence: 3 givenname: Fabien surname: Rollot fullname: Rollot, Fabien organization: Faculté de Médecine Lyon-Est, Université Claude Bernard Lyon 1, Observatoire Francais de la Sclérose En Plaques (OFSEP), Hôpital Pierre-Wertheimer – sequence: 4 givenname: Thais surname: Armangué fullname: Armangué, Thais organization: Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Pediatric Neuroimmunology Unit, Department of Neurology, Sant Joan de Deu Children’s Hospital, University of Barcelona – sequence: 5 givenname: Anne surname: Ruiz fullname: Ruiz, Anne organization: Lyon Neuroscience Research Center, U1028 INSERM, UMR5292 CNRS, FLUID Team – sequence: 6 givenname: Elisabeth surname: Maillart fullname: Maillart, Elisabeth organization: Department of Neurology, Pitié-Salpêtrière Hospital, APHP – sequence: 7 givenname: Caroline surname: Papeix fullname: Papeix, Caroline organization: Department of Neurology, Pitié-Salpêtrière Hospital, APHP – sequence: 8 givenname: Bertrand surname: Audoin fullname: Audoin, Bertrand organization: Aix Marseille University, APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, Service de Neurologie – sequence: 9 givenname: Helene surname: Zephir fullname: Zephir, Helene organization: Pôle des Neurosciences et de l’Appareil Locomoteur, CHU de Lille, Université de Lille, LIRIC, UMR 995 – sequence: 10 givenname: Damien surname: Biotti fullname: Biotti, Damien organization: Department of Neurology, Hôpital Pierre-Paul Riquet, University Hospital of Toulouse – sequence: 11 givenname: Jonathan surname: Ciron fullname: Ciron, Jonathan organization: Department of Neurology, Hôpital Pierre-Paul Riquet, University Hospital of Toulouse – sequence: 12 givenname: Francoise surname: Durand-Dubief fullname: Durand-Dubief, Francoise organization: Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon – sequence: 13 givenname: Nicolas surname: Collongues fullname: Collongues, Nicolas organization: Department of Neurology and Clinical Investigation Center, Strasbourg University Hospital – sequence: 14 givenname: Xavier surname: Ayrignac fullname: Ayrignac, Xavier organization: Multiple Sclerosis Clinic, Montpellier University Hospital – sequence: 15 givenname: Pierre surname: Labauge fullname: Labauge, Pierre organization: Multiple Sclerosis Clinic, Montpellier University Hospital – sequence: 16 givenname: Eric surname: Thouvenot fullname: Thouvenot, Eric organization: Department of Neurology, Hôpital Carémeau, Nimes University Hospital – sequence: 17 givenname: Bertrand surname: Bourre fullname: Bourre, Bertrand organization: Department of Neurology, Rouen University Hospital – sequence: 18 givenname: Alexis surname: Montcuquet fullname: Montcuquet, Alexis organization: Department of Neurology, Hôpital de Dupuytren – sequence: 19 givenname: Mikael surname: Cohen fullname: Cohen, Mikael organization: Université Côte d’Azur, Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, Service de Neurologie – sequence: 20 givenname: Romain surname: Deschamps fullname: Deschamps, Romain organization: Department of Neurology, Fondation A. De Rothschild – sequence: 21 givenname: Nuria surname: Solà-Valls fullname: Solà-Valls, Nuria organization: Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona – sequence: 22 givenname: Sara surname: Llufriu fullname: Llufriu, Sara organization: Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona – sequence: 23 givenname: Jerome surname: De Seze fullname: De Seze, Jerome organization: Department of Neurology and Clinical Investigation Center, Strasbourg University Hospital – sequence: 24 givenname: Yolanda surname: Blanco fullname: Blanco, Yolanda organization: Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona – sequence: 25 givenname: Sandra surname: Vukusic fullname: Vukusic, Sandra organization: Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM) – sequence: 26 givenname: Albert surname: Saiz fullname: Saiz, Albert organization: Center of Neuroimmunology, Service of Neurology, Hospital Clinic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona – sequence: 27 givenname: Romain surname: Marignier fullname: Marignier, Romain email: romain.marignier@chu-lyon.fr organization: Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Lyon Neuroscience Research Center, U1028 INSERM, UMR5292 CNRS, FLUID Team, Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31266527$$D View this record in MEDLINE/PubMed https://hal.sorbonne-universite.fr/hal-02180590$$DView record in HAL |
| BookMark | eNp9kk9v1DAQxSNURP_AB-CCInGBQ4rt2I5zQVpVpa20qAfgbE0ce9errL3YzlZ8e5ymVN0KVT7EmvzeG8_onRZHzjtdFO8xOsdY8C8Rk7ahFcJthRlhFX5VnOCGkoqglh49uR8XpzFuEKoJ4-RNcVxjwjkjzUnx43IPwwjJeld6U6agIW21S2XQcedd1KV1JfTjkGJ5Z9M61wfYRetW5ffbq2rRVRCjVxaS7sveRg1Rvy1eGxiifvfwPSt-fbv8eXFdLW-vbi4Wy0px1KaqRR2uMUcAmEBnOFUCiR5ppQ0jbW2Q0CAoVgwj2tC610YoBk1noMljE16fFTezb-9hI3fBbiH8kR6svC_4sJIQklWDlh1QU6tG9Fx0tBeiM6qDaQd5CbRWNHt9nb12Y7fVvcorCDAcmB7-cXYtV34vOUcNw002-DwbrJ_JrhdLOdUQwQKxFu1xZj89NAv-96hjklsblR4GcNqPURLCMBe0wSyjH2d0BXkM64zP3dWEywVr85oQ4hN1_h8qn15vrcqhMTbXDwQfno77-OB_wcgAngEVfIxBm0cEIzmFT87hkzl8cgqfnMZqnmmUTffRyq-xw4tKMitj7uJWOsiNH4PL4XlB9BejPOum |
| CitedBy_id | crossref_primary_10_1097_APO_0000000000000513 crossref_primary_10_1093_brain_awac480 crossref_primary_10_1038_s41582_021_00568_8 crossref_primary_10_1016_j_autrev_2024_103693 crossref_primary_10_1016_j_msard_2023_104739 crossref_primary_10_1212_NXI_0000000000001100 crossref_primary_10_1016_S1474_4422_21_00218_0 crossref_primary_10_1016_j_survophthal_2019_08_001 crossref_primary_10_1002_ana_25909 crossref_primary_10_1097_WNO_0000000000001684 crossref_primary_10_1016_j_msard_2020_102399 crossref_primary_10_1016_j_msard_2023_104571 crossref_primary_10_1007_s00415_020_10300_z crossref_primary_10_1002_ana_26731 crossref_primary_10_1001_jamaneurol_2022_0489 crossref_primary_10_3389_fimmu_2020_00119 crossref_primary_10_1055_a_1219_7907 crossref_primary_10_3390_ijms22010100 crossref_primary_10_5124_jkma_2024_67_8_517 crossref_primary_10_3389_fimmu_2024_1278867 crossref_primary_10_3389_fneur_2021_673339 crossref_primary_10_1080_14728214_2021_1919082 crossref_primary_10_1007_s11940_021_00667_3 crossref_primary_10_1136_bjophthalmol_2020_318769 crossref_primary_10_1007_s00415_020_10026_y crossref_primary_10_3390_children9050674 crossref_primary_10_1080_14737175_2024_2385941 crossref_primary_10_1212_NXI_0000000000000925 crossref_primary_10_1001_jamanetworkopen_2021_42780 crossref_primary_10_1016_j_jns_2024_122909 crossref_primary_10_12677_ACM_2024_143834 crossref_primary_10_1016_j_jneuroim_2022_577812 crossref_primary_10_1212_NXI_0000000000000674 crossref_primary_10_1136_jnnp_2020_324422 crossref_primary_10_1038_s41433_023_02477_0 crossref_primary_10_1055_a_2517_5229 crossref_primary_10_1002_acn3_51642 crossref_primary_10_3389_fneur_2021_662353 crossref_primary_10_1055_a_2297_0591 crossref_primary_10_1007_s11940_023_00776_1 crossref_primary_10_4103_aian_AIAN_627_19 crossref_primary_10_1007_s10384_022_00932_1 crossref_primary_10_1177_1756286420945135 crossref_primary_10_1002_ana_25648 crossref_primary_10_1212_WNL_0000000000201260 crossref_primary_10_2217_nmt_2020_0046 crossref_primary_10_1111_cei_13641 crossref_primary_10_1016_j_msard_2021_103035 crossref_primary_10_1016_j_msard_2021_103310 crossref_primary_10_3988_jcn_2024_0276 crossref_primary_10_33590_emjneurol_10305766 crossref_primary_10_1111_dmcn_14370 crossref_primary_10_1007_s00415_020_10236_4 crossref_primary_10_1111_ene_15684 crossref_primary_10_1038_s41572_020_0214_9 crossref_primary_10_3389_fneur_2020_499910 crossref_primary_10_1080_14737175_2021_1982697 crossref_primary_10_1016_j_msard_2024_105672 crossref_primary_10_1159_000519835 crossref_primary_10_1016_j_nerep_2022_100160 crossref_primary_10_1212_WNL_0000000000009768 crossref_primary_10_2147_IMCRJ_S459799 crossref_primary_10_3390_ijms241713368 crossref_primary_10_1016_j_msard_2021_103044 crossref_primary_10_3389_fimmu_2023_1211776 crossref_primary_10_1097_WCO_0000000000000828 crossref_primary_10_1007_s11910_019_1014_z crossref_primary_10_3389_fneur_2022_1044642 crossref_primary_10_3390_antib13020043 crossref_primary_10_1097_ICU_0000000000001007 crossref_primary_10_1136_jnnp_2022_330086 crossref_primary_10_47795_JYNJ6633 crossref_primary_10_59578_jmsni_2023_14_2_87 crossref_primary_10_1186_s12883_023_03294_4 crossref_primary_10_1212_WNL_0000000000009758 crossref_primary_10_5692_clinicalneurol_cn_001868 crossref_primary_10_1097_WCO_0000000000000813 crossref_primary_10_1055_a_2218_8352 crossref_primary_10_2214_AJR_20_24061 crossref_primary_10_1016_j_jneuroim_2021_577750 crossref_primary_10_1007_s11940_021_00672_6 crossref_primary_10_12677_ACM_2022_122190 crossref_primary_10_1177_20552173211032334 crossref_primary_10_1097_WNO_0000000000001772 crossref_primary_10_1172_jci_insight_165373 crossref_primary_10_1177_13524585241226830 crossref_primary_10_59578_jmsni_2023_14_1_24 crossref_primary_10_1007_s10072_020_04828_1 crossref_primary_10_1016_j_msard_2021_103462 crossref_primary_10_1007_s00115_021_01090_4 crossref_primary_10_1016_j_msard_2025_106334 crossref_primary_10_1080_14712598_2020_1749259 crossref_primary_10_1111_ene_15355 crossref_primary_10_1016_j_msard_2021_103229 crossref_primary_10_1097_WCO_0000000000001052 crossref_primary_10_1016_j_ejpn_2020_10_005 crossref_primary_10_1016_j_msard_2020_102376 crossref_primary_10_1097_WCO_0000000000000766 crossref_primary_10_3390_ijms21218409 crossref_primary_10_14412_2074_2711_2022_1S_21_28 crossref_primary_10_1016_j_msard_2021_103356 crossref_primary_10_1186_s40478_019_0786_3 crossref_primary_10_1016_j_conb_2022_102643 crossref_primary_10_1038_s41423_020_0510_z crossref_primary_10_3389_fimmu_2021_686466 crossref_primary_10_1097_WNO_0000000000001234 crossref_primary_10_1177_17562864211054157 crossref_primary_10_1212_WNL_0000000000012175 crossref_primary_10_1007_s11910_024_01344_z crossref_primary_10_1016_j_msard_2021_103191 crossref_primary_10_1111_cen3_12623 crossref_primary_10_3389_fimmu_2022_953993 crossref_primary_10_3389_fneur_2020_00450 crossref_primary_10_3988_jcn_2022_18_3_280 crossref_primary_10_5692_clinicalneurol_cn_001724 |
| Cites_doi | 10.1212/WNL.0b013e31822a2780 10.1001/jamaneurol.2014.2057 10.1007/s00415-016-8147-7 10.1177/1352458514555785 10.1186/s12974-016-0719-z 10.1002/sim.3697 10.1212/WNL.0000000000004312 10.1186/1742-2094-8-184 10.1001/archneurol.2010.188 10.1093/brain/awx276 10.1136/jnnp-2017-316880 10.1212/NXI.0000000000000257 10.1212/WNL.0b013e3182152881 10.1371/journal.pone.0098192 10.1001/jamaneurol.2013.5857 10.1001/jamaneurol.2017.4601 10.1186/s12974-018-1144-2 10.1097/WCO.0000000000000455 10.1002/sim.7084 10.1177/1352458513484547 10.1016/j.jns.2014.01.035 10.1177/1352458516678474 10.1038/nrneurol.2014.141 10.1007/s00415-017-8583-z 10.1212/WNL.0000000000000101 10.1212/NXI.0000000000000081 10.1212/WNL.0000000000005560 10.1212/WNL.0000000000001729 10.1186/s12974-016-0718-0 10.1212/NXI.0000000000000163 10.1007/s00415-015-7852-y 10.1001/jamaneurol.2016.1637 10.1212/NXI.0000000000000225 10.1002/ana.22366 10.1001/jamaneurol.2017.3196 10.1111/j.1468-1331.2010.03066.x 10.1177/1352458515602337 10.1093/brain/aww350 10.1186/s12974-016-0717-1 10.1007/s00415-013-7169-7 10.1002/ana.21102 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1186/s12974-019-1525-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1742-2094 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_ba4f3c78d68b4d88bfcba266552743c4 PMC6607517 oai_HAL_hal_02180590v1 A592930065 31266527 10_1186_s12974_019_1525_1 |
| Genre | Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7X8 1XC 2VQ 4.4 AHSBF H13 IPNFZ RIG VOOES 5PM |
| ID | FETCH-LOGICAL-c609t-90b13160aa12abf64c808d0ecef5293f08ea841c5104743def8c5a7bfa7297263 |
| IEDL.DBID | M48 |
| ISSN | 1742-2094 |
| IngestDate | Wed Aug 27 01:31:00 EDT 2025 Thu Aug 21 13:54:27 EDT 2025 Fri Sep 12 12:45:17 EDT 2025 Fri Sep 05 06:50:31 EDT 2025 Tue Jun 17 21:33:40 EDT 2025 Tue Jun 10 20:47:28 EDT 2025 Thu Jan 02 23:00:37 EST 2025 Tue Jul 01 02:54:30 EDT 2025 Thu Apr 24 23:09:06 EDT 2025 Sat Sep 06 07:29:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Multiple sclerosis Treatment response Neuromyelitis optica Propensity score MOG antibodies |
| Language | English |
| License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c609t-90b13160aa12abf64c808d0ecef5293f08ea841c5104743def8c5a7bfa7297263 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-6741-0958 0000-0003-4029-2012 0000-0003-3834-2981 0000-0001-7759-8555 0000-0002-7197-7578 0000-0001-8671-7747 0000-0003-4074-6125 0000-0002-9860-7657 0000-0002-2860-1700 0000-0002-3985-1297 0000-0002-2459-2480 0000-0002-5967-2800 0000-0002-3386-6308 0000-0001-7337-7122 0000-0002-3683-5582 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12974-019-1525-1 |
| PMID | 31266527 |
| PQID | 2251684715 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ba4f3c78d68b4d88bfcba266552743c4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6607517 hal_primary_oai_HAL_hal_02180590v1 proquest_miscellaneous_2251684715 gale_infotracmisc_A592930065 gale_infotracacademiconefile_A592930065 pubmed_primary_31266527 crossref_primary_10_1186_s12974_019_1525_1 crossref_citationtrail_10_1186_s12974_019_1525_1 springer_journals_10_1186_s12974_019_1525_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-07-02 |
| PublicationDateYYYYMMDD | 2019-07-02 |
| PublicationDate_xml | – month: 07 year: 2019 text: 2019-07-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of neuroinflammation |
| PublicationTitleAbbrev | J Neuroinflammation |
| PublicationTitleAlternate | J Neuroinflammation |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | M Trojano (1525_CR41) 2007; 61 HL Pellkofer (1525_CR33) 2011; 76 N Collongues (1525_CR35) 2015; 22 M Sepúlveda (1525_CR8) 2016; 263 CH Polman (1525_CR25) 2011; 69 R Marignier (1525_CR27) 2017; 30 KC Wang (1525_CR39) 2014; 9 LB Krupp (1525_CR26) 2013; 19 S Mader (1525_CR14) 2011; 8 A Montcuquet (1525_CR32) 2016; 23 V Damato (1525_CR36) 2016; 73 J Kitley (1525_CR1) 2014; 71 S-Y Huh (1525_CR31) 2014; 71 C Trebst (1525_CR21) 2014; 261 DM Wingerchuk (1525_CR24) 2015; 85 S Jarius (1525_CR12) 2016; 13 J Sellner (1525_CR20) 2010; 17 Á Cobo-Calvo (1525_CR29) 2017; 264 R Höftberger (1525_CR4) 2015; 21 A Cobo-Calvo (1525_CR13) 2018; 90 S-M Kim (1525_CR10) 2015; 2 H Zéphir (1525_CR34) 2015; 262 M Sepúlveda (1525_CR19) 2016; 3 Y Hacohen (1525_CR17) 2018; 75 PC Austin (1525_CR23) 2009; 28 MC Papadopoulos (1525_CR28) 2014; 10 C Costanzi (1525_CR30) 2011; 77 S Ramanathan (1525_CR18) 2017; 89 DK Sato (1525_CR2) 2014; 82 M Jurynczyk (1525_CR9) 2017; 140 M Spadaro (1525_CR37) 2016; 3 S Jarius (1525_CR16) 2016; 13 M Jurynczyk (1525_CR6) 2017; 140 S Jarius (1525_CR7) 2018; 15 SHM Hamid (1525_CR11) 2017; 75 S Jarius (1525_CR15) 2016; 13 PC Austin (1525_CR22) 2016; 35 J Palace (1525_CR38) 2010; 67 J Kitley (1525_CR40) 2014; 339 Y Hacohen (1525_CR3) 2015; 2 E-M Hennes (1525_CR5) 2017; 89 |
| References_xml | – volume: 77 start-page: 659 year: 2011 ident: 1525_CR30 publication-title: Neurology doi: 10.1212/WNL.0b013e31822a2780 – volume: 71 start-page: 1372 year: 2014 ident: 1525_CR31 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2014.2057 – volume: 263 start-page: 1349 year: 2016 ident: 1525_CR8 publication-title: J Neurol doi: 10.1007/s00415-016-8147-7 – volume: 21 start-page: 866 year: 2015 ident: 1525_CR4 publication-title: Mult Scler doi: 10.1177/1352458514555785 – volume: 13 start-page: 281 year: 2016 ident: 1525_CR15 publication-title: J Neuroinflammation doi: 10.1186/s12974-016-0719-z – volume: 28 start-page: 3083 year: 2009 ident: 1525_CR23 publication-title: Stat Med doi: 10.1002/sim.3697 – volume: 89 start-page: 900 year: 2017 ident: 1525_CR5 publication-title: Neurology doi: 10.1212/WNL.0000000000004312 – volume: 8 start-page: 184 year: 2011 ident: 1525_CR14 publication-title: J Neuroinflammation doi: 10.1186/1742-2094-8-184 – volume: 67 start-page: 1016 year: 2010 ident: 1525_CR38 publication-title: Arch Neurol doi: 10.1001/archneurol.2010.188 – volume: 140 start-page: 3128 year: 2017 ident: 1525_CR9 publication-title: Brain doi: 10.1093/brain/awx276 – volume: 89 start-page: 127 year: 2017 ident: 1525_CR18 publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2017-316880 – volume: 3 start-page: e257 year: 2016 ident: 1525_CR37 publication-title: Neurol Neuroimmunol Neuroinflammation doi: 10.1212/NXI.0000000000000257 – volume: 76 start-page: 1310 year: 2011 ident: 1525_CR33 publication-title: Neurology doi: 10.1212/WNL.0b013e3182152881 – volume: 9 start-page: e98192 year: 2014 ident: 1525_CR39 publication-title: PLoS One doi: 10.1371/journal.pone.0098192 – volume: 71 start-page: 276 year: 2014 ident: 1525_CR1 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2013.5857 – volume: 75 start-page: 478 year: 2018 ident: 1525_CR17 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2017.4601 – volume: 15 start-page: 134 year: 2018 ident: 1525_CR7 publication-title: J Neuroinflammation doi: 10.1186/s12974-018-1144-2 – volume: 30 start-page: 208 year: 2017 ident: 1525_CR27 publication-title: Curr Opin Neurol doi: 10.1097/WCO.0000000000000455 – volume: 35 start-page: 5642 year: 2016 ident: 1525_CR22 publication-title: Stat Med doi: 10.1002/sim.7084 – volume: 19 start-page: 1261 year: 2013 ident: 1525_CR26 publication-title: Mult Scler doi: 10.1177/1352458513484547 – volume: 339 start-page: 223 year: 2014 ident: 1525_CR40 publication-title: J Neurol Sci doi: 10.1016/j.jns.2014.01.035 – volume: 23 start-page: 1377 year: 2016 ident: 1525_CR32 publication-title: Mult Scler doi: 10.1177/1352458516678474 – volume: 10 start-page: 493 year: 2014 ident: 1525_CR28 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2014.141 – volume: 264 start-page: 1945 year: 2017 ident: 1525_CR29 publication-title: J Neurol doi: 10.1007/s00415-017-8583-z – volume: 82 start-page: 474 year: 2014 ident: 1525_CR2 publication-title: Neurology. doi: 10.1212/WNL.0000000000000101 – volume: 2 start-page: e81 year: 2015 ident: 1525_CR3 publication-title: Neurol Neuroimmunol Neuroinflammation doi: 10.1212/NXI.0000000000000081 – volume: 90 start-page: e1858 year: 2018 ident: 1525_CR13 publication-title: Neurology doi: 10.1212/WNL.0000000000005560 – volume: 85 start-page: 177 year: 2015 ident: 1525_CR24 publication-title: Neurology doi: 10.1212/WNL.0000000000001729 – volume: 13 start-page: 280 year: 2016 ident: 1525_CR16 publication-title: J Neuroinflammation doi: 10.1186/s12974-016-0718-0 – volume: 2 start-page: e163 year: 2015 ident: 1525_CR10 publication-title: Neurol Neuroimmunol Neuroinflammation doi: 10.1212/NXI.0000000000000163 – volume: 262 start-page: 2329 year: 2015 ident: 1525_CR34 publication-title: J Neurol doi: 10.1007/s00415-015-7852-y – volume: 73 start-page: 1342 year: 2016 ident: 1525_CR36 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2016.1637 – volume: 3 start-page: e225 year: 2016 ident: 1525_CR19 publication-title: Neurol Neuroimmunol Neuroinflammation doi: 10.1212/NXI.0000000000000225 – volume: 69 start-page: 292 year: 2011 ident: 1525_CR25 publication-title: Ann Neurol doi: 10.1002/ana.22366 – volume: 75 start-page: 65 year: 2017 ident: 1525_CR11 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2017.3196 – volume: 17 start-page: 1019 year: 2010 ident: 1525_CR20 publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2010.03066.x – volume: 22 start-page: 955 year: 2015 ident: 1525_CR35 publication-title: Mult Scler doi: 10.1177/1352458515602337 – volume: 140 start-page: 617 year: 2017 ident: 1525_CR6 publication-title: Brain doi: 10.1093/brain/aww350 – volume: 13 start-page: 279 year: 2016 ident: 1525_CR12 publication-title: J Neuroinflammation doi: 10.1186/s12974-016-0717-1 – volume: 261 start-page: 1 year: 2014 ident: 1525_CR21 publication-title: J Neurol doi: 10.1007/s00415-013-7169-7 – volume: 61 start-page: 300 year: 2007 ident: 1525_CR41 publication-title: Ann Neurol doi: 10.1002/ana.21102 |
| SSID | ssj0032562 |
| Score | 2.5689409 |
| Snippet | Background
Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic... Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is... Background Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic... BACKGROUND:Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic... Abstract Background Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the... |
| SourceID | doaj pubmedcentral hal proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 134 |
| SubjectTerms | Adolescent Adult Aged Autoantibodies - blood Biomedical and Life Sciences Biomedicine Brain research Cohort Studies Development and progression Drug therapy Female Humans Immunology Immunosuppressive agents Immunosuppressive Agents - therapeutic use Immunotherapy Life Sciences Male Middle Aged MOG antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - diagnosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Myelin-Oligodendrocyte Glycoprotein - blood Nervous system diseases Neurobiology Neurology Neuromyelitis optica Neuromyelitis Optica - blood Neuromyelitis Optica - diagnosis Neuromyelitis Optica - drug therapy Neurons and Cognition Neurosciences Patient outcomes Propensity score Retrospective Studies Rituximab - therapeutic use Santé publique et épidémiologie Treatment Outcome Treatment response Young Adult |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagB8QFQXkttJVBSEggq3b8iHNcUMsKsXCASr1ZfkWtVGWr7pbfz0zijRoq4MI1fsSZGXs-xzOfCXkjo2i01mC8KSamqpiZ123FPBcBCc6VsZicvPxqFifq86k-vXHVF8aEDfTAg-AOg1etjLVNxgaVrA1tDB68CjKHKRl7JlDe8O1maliDJTjyqpxhCmsO1-DVaoy2aBje98PExAv1ZP3jknz3DCMib8PN21GTvx2d9h7p-CF5UKAknQ-f8Ijcyd0uubcsh-WPyfejkcmbrlo6hpTTqyEuNtPzjvb8G2uKv2Mp5rVc4r8Duvz2ic0D80V3OdFykPOEnBwf_fi4YOUOBRYNbzas4UFIYbj3ovKhNSpabhPPMbcaPH3LbfZWiaiRskHJlFsbta9D6wF115WRT8lOt-ryc0JhJxKSyQBZuFe50r4BdJmETTGkxH09I3wrUxcLwTjec3Hh-o2GNW5QgwM1OFSDEzPybmxyObBr_K3yB1TUWBGJsfsHYC6umIv7l7nMyFtUs8PpC4OLvmQhwCciEZaba8CLEoHZjOxNasK0i5Pi12Aok8Es5l8cPkPYhDm9P2HIr7Z25LA9BrR1eXW9drCMCoPIADp6NtjV2JcUOOAKBFpPLG7ysmlJd37WU4MbAxBQQMv3W9t0ZU1a_1mwL_6HYF-S-xXvE-IYr_bIzubqOu8DXtuEg35q_gIdLDmg priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA96gvgifrvnKVEEQQkmbZKmj-ty5yKuPujBvYV8cgfSPW73_Ptvps0W66nga5u0aWYy80tn5hdCXtdBtEopUN4YIpNVSMypXDHHhUeCc6kNFievvujlsfx0ok4KWTTWwvwavxdGv9-AP2owT6JleFIPg43OLQV2F5V5oRc7o1uD565K0PKP3SZup2fnH23wzVNMgbyOL6-nSf4WK-1d0NE9crdgRzofhH2f3EjdA3J7VaLjD8m3w5G6m64zHXPI6cWQCJvoWUd7wo0Nxf-vFAtZzvFnAV19_cjmnrkirBRpidw8IsdHh98XS1YOTWBB83bLWu5FLTR3TlTOZy2D4SbyFFJW4NozN8kZKYJCjgZZx5RNUK7x2QHMbipdPyZ73bpLTwmFrYePOgFG4U6mSrkW4GQUJgYfI3fNjPDdnNpQGMXxYIsftt9ZGG0HMVgQg0UxWDEjb8cu5wOdxr8af0BBjQ2RCbu_AApiy8ICZy9zHRoTtfEyGuNz8A5QBzLLyTrIGXmDYra4XmFwwZWyA_hEZL6ycwUAsUYkNiMHk5awzsLk9itQlMlglvPPFq8hTsIi3p8w5Jc7PbLYHzPYurS-3Fiwm0IjFIAHPRn0anxWLXDAFUxoM9G4ycumd7qz054LXGvAfAJ6vtvppi1GaPP3id3_r9bPyJ2K96VujFcHZG97cZmeAxLb-hf9GrwCuOopDw priority: 102 providerName: Springer Nature |
| Title | Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease |
| URI | https://link.springer.com/article/10.1186/s12974-019-1525-1 https://www.ncbi.nlm.nih.gov/pubmed/31266527 https://www.proquest.com/docview/2251684715 https://hal.sorbonne-universite.fr/hal-02180590 https://pubmed.ncbi.nlm.nih.gov/PMC6607517 https://doaj.org/article/ba4f3c78d68b4d88bfcba266552743c4 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELf2ISFeEN8URmUQEhLI4CSO4zwglFUdVUUHYlTqm-WvsElTOtoOwX_PXZJGCht7quTYruO7i3_23f1MyKvERXmapqC83nkmYheYScuYGR5ZJDgXUmFy8uxYTuZiukgXO2R7vVU7getrt3Z4n9R8df7u988_H8HgP9QGr-T7NaxZGcZS5Axv82GwGdqv3UUYySc6p0ICq3vc5EfGoBy5aJ2c13bRW6ZqNv_um717iiGTV_Ho1bDKf3yr9ZJ1dJfcabEmLRrluEd2QnWf3Jq13vQH5GTcUX3TZUm7mHO6agJnAz2raE3QsaZ4Xksx8eUCDxfo7MsnVlhmWuEGT1tPz0MyPxp_H01Ye8kCc5LnG5ZzGyWR5MZEsbGlFE5x5XlwoUwBCpRcBaNE5FLkdBCJD6VyqclsaQCWZ7FMHpG9almFJ4TCVsV6GQDTcCNCnJoc4KePlHfWe26yAeHbOdWuZSDHizDOdb0TUVI3YtAgBo1i0NGAvOmaXDT0GzdVPkRBdRWRObsuWK5-6NYQARyIMnGZ8lJZ4ZWypbMGUAoy0YnEiQF5jWLWqHEwOGfaNAV4RWTK0kUKgDJB5DYgB72aYJeu9_glKEpvMJPis8YyxFWY9PsLhvxiq0ca22PEWxWWl2sN39lIInSAjh43etX1lUQ44BgmNOtpXO_P-k-qs9OaO1xKwIgRtHy71U29tbn_T-zTm9_0Gbkd8zoXjvH4gOxtVpfhOUC1jR2S3WyRDcl-UUxPpvB7OD7--g1KR3I0rI8_hrWJ_gUo1Dr9 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSMAF8WahgEFISCCrdmI7znFZtSywWw60Um-WX1EroWzV3fL7mUm8EaGAxNWxHccz9nzOzHwm5E0ZRK2UAuWNITJZhMScagrmuPBIcC61weTk5aGeH8vPJ-okk0VjLsyv_nth9N4a7FGFcRI1w5t6GBx0bqDjEmnyZ3q23XRLsNxFdlr-sdnI7HTs_MMefP0UQyCv4surYZK_-Uo7E3Rwl9zJ2JFOe2HfI9dSe5_cXGbv-APybX-g7qarhg4x5PSiD4RN9KylHeHGmuL_V4qJLOf4s4Auv35kU89cFlaKNHtuHpLjg_2j2ZzlSxNY0LzesJp7UQrNnROF842WwXATeQqpUWDaG26SM1IEhRwNsoypMUG5yjcOYHZV6PIR2WlXbXpCKBw9fNQJMAp3MhXK1QAnozAx-Bi5qyaEb-fUhswojhdbfLfdycJo24vBghgsisGKCXk3NDnv6TT-VfkDCmqoiEzYXQEoiM0LC4y9bMpQmaiNl9EY3wTvAHUgs5wsg5yQtyhmi-sVBhdcTjuAT0TmKztVABBLRGITsjuqCessjB6_BkUZDWY-XVgsQ5yESbw_YMivtnpksT1GsLVpdbm2sG8KjVAAOnrc69XQVylwwAVMaDXSuNHLxk_as9OOC1xrwHwCWr7f6qbNm9D67xP79L9qvyS35kfLhV18OvzyjNwueJf2xnixS3Y2F5fpOaCyjX_Rrcef2c8r_g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgkyZeEN8rDDAICQkUzU4cx3kMsFLKOpDGpL1Z_gqbhNKq7fj7uUucSGGAxGtiJ47vzvdz7u5nQl5ljpd5noPyeucTkbqQmLxOE8O4RYJzIRUWJy9O5OxMzM_z83jO6abPdu9Dkl1NA7I0NdvDla87E1fycANeqsDsiTLB83sS2P7sqrwsYfe1W1Xz03m_GGfg0dMYzPxjx5E7aln7h7X55gWmRl7HndfTJ3-LobauaXqH3I6YkladEtwlN0Jzj-wtYtT8Pjk9Gii96bKmQ245XXcJsoFeNrQl4thQ_C9LscBlhT8R6OLLx6SyiYlCDJ7GiM4DcjY9-vZ-lsTDFBInWblNSmZ5xiUzhqfG1lI4xZRnwYU6B5dfMxWMEtzlyN0gMh9q5XJT2NoA_C5SmT0kO82yCfuEwpbEehkAuzAjQpqbEmCm58o76z0zxYSwfk61i0zjeODFD93uOJTUnRg0iEGjGDSfkDdDl1VHs_Gvxu9QUENDZMhuLyzX33U0OAABos5cobxUVnilbO2sATSCjHMic2JCXqOYNdoxDM6ZWI4An4iMWLrKAThmiNAm5GDUEuzPjW6_BEUZDWZWHWu8hvgJi3t_wpBf9HqksT9mtjVhebXRsJ5yiRABHvSo06vhWRnHAacwocVI40YvG99pLi9ajnApAQty6Pm2100dF6fN3yf28X-1fk72vn6Y6uNPJ5-fkFspa6vhEpYekJ3t-io8BbC2tc-iQf4CKqg1vA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+treatment+response+in+adults+with+relapsing+MOG-Ab-associated+disease&rft.jtitle=Journal+of+neuroinflammation&rft.au=Cobo-Calvo%2C+Alvaro&rft.au=Sep%C3%BAlveda%2C+Mar%C3%ADa&rft.au=Rollot%2C+Fabien&rft.au=Armangu%C3%A9%2C+Thais&rft.date=2019-07-02&rft.pub=BioMed+Central+Ltd&rft.issn=1742-2094&rft.eissn=1742-2094&rft.volume=16&rft.issue=1&rft_id=info:doi/10.1186%2Fs12974-019-1525-1&rft.externalDocID=A592930065 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-2094&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-2094&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-2094&client=summon |